MedTrace Logo

High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma

NCT00447356 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2013-05-13

No results posted yet for this study

Summary

This randomized phase III trial is studying high dose interferon alfa to see how well it works compared to observation only in treating patients with stage II or stage III melanoma that has been completely removed by surgery.

Conditions

  • Melanoma (Skin)

Interventions

DRUG

recombinant interferon alfa

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Hackensack Meridian Health

    lead OTHER

Principal Investigators

  • David S. Siegel, MD · Hackensack Meridian Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00447356 on ClinicalTrials.gov